Finasteride vs Spironolactone: Head-to-Head Efficacy for Skin, Hair, and Hormonal Acne

How These Two Drugs Work: Mechanism of Action

Finasteride and spironolactone both reduce androgen signaling, but they interrupt different steps in the pathway. Finasteride inhibits the enzyme 5-alpha reductase type II, which converts testosterone into dihydrotestosterone (DHT). Spironolactone competes with androgens at the receptor level and also weakly inhibits androgen biosynthesis in the adrenal gland.

The distinction matters clinically. Finasteride lowers serum DHT by roughly 70% without significantly changing total testosterone levels 1. That selectivity makes it effective for conditions driven specifically by DHT, like androgenetic alopecia (AGA) in men, where miniaturization of the hair follicle is a DHT-dependent process. It does not, however, block testosterone itself or other androgens from activating the androgen receptor.

Spironolactone takes a broader approach. By sitting on the androgen receptor, it blocks testosterone, DHT, and other androgens from binding, regardless of which enzyme produced them 2. This wider blockade is why dermatologists favor it for hormonal acne in women, where multiple androgen species contribute to sebum overproduction. The drug also has mineralocorticoid receptor antagonist activity, which is its original pharmacological purpose and the source of its potassium-sparing diuretic effect.

A 2020 systematic review in the Journal of the American Academy of Dermatology identified spironolactone as the most commonly prescribed antiandrogen for female acne, with response rates ranging from 50% to 100% depending on the study design and dose used 3. Finasteride, by contrast, has minimal data supporting its use in acne of any kind.

Efficacy for Hair Loss

For male androgenetic alopecia, finasteride 1 mg daily is one of the most studied treatments available. The Kaufman et al. trial, a five-year extension of the original key study, demonstrated sustained increases in hair count on the vertex scalp compared to men who received placebo 1. At two years, finasteride-treated men had a mean increase of 138 hairs in a 5.1 cm² target area, while placebo-treated men lost a mean of 72 hairs. That gap widened over the full five years.

Spironolactone is not FDA-approved for hair loss but sees substantial off-label use in women with female-pattern hair loss (FPHL). A retrospective study published in the Journal of the American Academy of Dermatology found that 74.3% of women treated with spironolactone for FPHL reported stabilization or improvement at one year, though the evidence base consists almost entirely of observational and retrospective data rather than placebo-controlled trials 4.

The practical divide is sharp. Finasteride dominates in male AGA, where DHT is the primary driver. Spironolactone fills the gap for women, where finasteride is rarely prescribed because of its teratogenic risk and because female hair loss often involves androgen receptor sensitivity rather than elevated DHT alone. The two drugs almost never compete for the same patient in clinical practice.

Efficacy for Hormonal Acne

Spironolactone has the stronger evidence profile for acne. Layton et al. (2017) confirmed its efficacy in adult women with hormonal acne at doses of 50 to 200 mg daily, noting significant reductions in inflammatory lesion counts 2. A Cochrane-registered systematic review identified spironolactone as superior to placebo for reducing both total and inflammatory acne lesions in women, though the authors noted that evidence quality remained moderate overall 5.

"Spironolactone at 100 mg daily is our most reliable oral option for women with jawline-predominant acne who have failed topical retinoids and antibiotics," stated the 2023 American Academy of Dermatology guidelines update on acne management 6.

Finasteride has almost no acne-specific data. A few case reports and small case series have explored finasteride 5 mg (the BPH dose, not the AGA dose) in women with severe hirsutism and acne, but sample sizes are too small to draw efficacy conclusions. The drug has never been tested against spironolactone or against placebo specifically for acne in any adequately powered trial.

The bottom line: if the primary complaint is hormonal acne, the clinical evidence points to spironolactone. Finasteride has no meaningful role in acne management under current evidence.

Dosing and Onset Differences

Finasteride for hair loss is dosed at 1 mg daily. Onset of visible improvement typically takes three to six months, and the drug must be continued indefinitely to maintain results. Discontinuation leads to a return of hair loss within 6 to 12 months as DHT levels normalize. The 5 mg formulation (Proscar) is approved only for benign prostatic hyperplasia and is sometimes split off-label for cost savings, though the FDA has not endorsed that practice.

Spironolactone dosing for dermatologic indications usually starts at 25 to 50 mg daily, titrating up to 100 or 200 mg based on clinical response and tolerability. Acne improvement generally becomes apparent by three months, with peak effect at six to nine months. As with finasteride, acne tends to recur after discontinuation, leading many women to remain on long-term maintenance therapy at the lowest effective dose.

Both drugs require patience. Neither produces rapid visible results, and both require months of consistent use before efficacy can be assessed. The American Academy of Dermatology recommends waiting at least three to six months before evaluating response to either medication 6.

Side Effect Profiles

The side effect profiles barely overlap. Finasteride's primary concerns are sexual: decreased libido, erectile dysfunction, and reduced ejaculate volume have been reported in 1.3% to 3.8% of men in controlled trials 1. A contested entity called "post-finasteride syndrome" describes persistent sexual, neurological, and psychological symptoms after drug discontinuation. The FDA added a warning about this in 2012, though the existence and mechanism of the syndrome remain debated in the literature 7.

Spironolactone's side effects reflect its mineralocorticoid and hormonal activity. The most clinically significant risk is hyperkalemia, particularly in patients with renal impairment or those taking ACE inhibitors, ARBs, or potassium supplements. Breast tenderness occurs in up to 20% of women at doses above 100 mg. Menstrual irregularity is common, reported in 10% to 40% of premenopausal women depending on the dose 3.

"The risk of clinically significant hyperkalemia in healthy young women on spironolactone for acne is extremely low," noted a 2015 analysis in JAMA Dermatology that questioned the necessity of routine potassium monitoring in this population 8. The study found that among 974 healthy women aged 18 to 45 taking spironolactone at dermatologic doses, not a single case of potassium above 6.0 mEq/L was recorded.

Both drugs carry FDA pregnancy category X warnings. Finasteride can cause ambiguous genitalia in a male fetus exposed during the first trimester. Spironolactone's androgen receptor blockade poses a similar theoretical risk of feminizing a male fetus. Reliable contraception is mandatory for premenopausal women taking either drug.

Who Gets Which Drug: Patient Selection

Sex is the single biggest determinant. The clinical reality is that finasteride is prescribed almost exclusively to men, and spironolactone almost exclusively to women. This is not arbitrary. It reflects three factors working in the same direction.

First, indication alignment. Most men seeking antiandrogen therapy want hair preservation, and finasteride has strong RCT data for male AGA. Most women seeking antiandrogen therapy want acne control or hair stabilization, and spironolactone covers both.

Second, tolerability. Spironolactone causes gynecomastia and breast tenderness in men, making it poorly tolerated for chronic use at dermatologic doses. Finasteride's sexual side effects are more relevant to male patients but do not produce feminizing effects.

Third, safety. Finasteride's teratogenicity creates a regulatory and medicolegal barrier to prescribing it to women of childbearing age, even though a small body of evidence suggests it may work for female AGA at 2.5 to 5 mg daily 9. Spironolactone is teratogenic too, but decades of use in young women for acne and PCOS have established comfort with the drug-plus-contraception workflow.

The overlap zone is narrow: postmenopausal women with AGA who cannot tolerate minoxidil. In that population, both finasteride (off-label at 1 to 5 mg) and spironolactone (100 to 200 mg) are reasonable options, and the choice may come down to comorbidities, specifically whether the patient would benefit from or be harmed by spironolactone's diuretic and potassium-raising effects.

Monitoring Requirements

Finasteride requires minimal monitoring. A baseline PSA level is recommended in men over 40 because finasteride roughly halves PSA values, which can mask prostate cancer detection on screening 10. Beyond that, no routine blood work is standard for healthy men taking 1 mg daily.

Spironolactone has traditionally required periodic potassium and renal function testing, though this practice is evolving. The 2015 JAMA Dermatology analysis 8 argued that in healthy women under 45 with normal baseline renal function, routine potassium monitoring adds cost without clinical benefit. Some dermatology departments have already adopted a "check once at baseline, then only if clinically indicated" protocol. Patients with kidney disease, heart failure, or concurrent potassium-sparing medications still require regular monitoring.

Blood pressure checks are warranted for spironolactone patients, especially at initiation. Clinically significant hypotension is uncommon at dermatologic doses but can occur, particularly in patients who are already normotensive-to-low.

Can the Two Drugs Be Combined?

Combination therapy is rare and poorly studied. A few case series have described finasteride plus spironolactone in transgender women (male-to-female hormone therapy), where the goal is maximal androgen suppression 11. In the dermatologic setting, there is no published evidence supporting combination use for acne or hair loss.

The theoretical rationale exists: finasteride reduces DHT production while spironolactone blocks the androgen receptor, covering both upstream and downstream targets. In practice, the sex-specific prescribing patterns described above mean the combination is almost never relevant. A man with AGA would not typically receive spironolactone, and a woman with hormonal acne would not typically receive finasteride.

If a clinician were considering dual therapy in an unusual case, additive side effects on potassium (spironolactone) and sexual function (both drugs) would need careful weighing. No guidelines endorse this approach for skin or hair indications.

Cost and Access

Generic finasteride 1 mg is inexpensive. GoodRx data from 2026 shows a typical cash price of $4 to $15 for a 30-day supply. Insurance coverage is inconsistent because many plans classify hair loss treatment as cosmetic.

Generic spironolactone is similarly affordable: approximately $4 to $20 for a 30-day supply of 100 mg tablets. Because it has FDA-approved indications (heart failure, edema, primary hyperaldosteronism), insurance coverage is generally better than for finasteride, though dermatologic use may still require prior authorization at some plans.

Both drugs are available through telehealth platforms, including HealthRX. Neither requires in-person procedures or injection visits, making them accessible options for patients in areas with limited dermatology availability. The low cost of both generics means that efficacy, tolerability, and sex-specific safety profiles, not price, should drive the prescribing decision.